Acute changes in renal function associated with deferoxamine therapy
- PMID: 2486554
- DOI: 10.1001/archpedi.1989.02150210113029
Acute changes in renal function associated with deferoxamine therapy
Abstract
In three patients who received intravenous deferoxamine there was a twofold to eightfold increase in plasma creatinine level and a parallel decrease in creatinine clearance that resolved when treatment with the drug was discontinued. In two thalassemic patients, diuresis was evident by urine output exceeding fluid intake. The mechanism was studied in dogs that exhibited an acute and significant decrease in inulin and para-aminohippuric acid clearances induced by intravenous deferoxamine. Saline diuresis could prevent the decrease in the glomerular filtration rate but not the decrease in renal blood flow caused by deferoxamine. Deferoxamine induced an acute increase in the fractional excretion of sodium, potassium, chloride, phosphate, and urate, which may explain the relative diuresis observed in two of the patients. In a subsequent experiment, ferrioxamine induced an increase in the fractional excretion of sodium and chloride but did not affect the glomerular filtration rate and renal blood flow. Our studies suggest that adequate hydration may be needed to preserve renal hemodynamics during intravenous deferoxamine therapy. Repeated measurements of renal function should accompany treatment with this agent.
Comment in
-
Acute changes in renal function associated with deferoxamine therapy.Am J Dis Child. 1990 Oct;144(10):1069-70. doi: 10.1001/archpedi.1990.02150340011005. Am J Dis Child. 1990. PMID: 2264886 No abstract available.
Similar articles
-
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.Acta Haematol. 2010;123(3):148-52. doi: 10.1159/000287238. Epub 2010 Feb 24. Acta Haematol. 2010. PMID: 20185899
-
The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.Int J Hematol. 1991 Oct;54(5):371-5. Int J Hematol. 1991. PMID: 1756248
-
Renal function correlates of postnatal diuresis in preterm infants.Pediatrics. 1988 Jul;82(1):50-8. Pediatrics. 1988. PMID: 3288958 Review.
-
Response to long-term deferoxamine therapy in thalassemia.J Pediatr. 1981 Nov;99(5):689-94. doi: 10.1016/s0022-3476(81)80385-x. J Pediatr. 1981. PMID: 7299539
-
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.Drug Des Devel Ther. 2016 Jan 29;10:465-81. doi: 10.2147/DDDT.S79458. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26893541 Free PMC article. Review.
Cited by
-
Site-specific intestinal DMT1 silencing to mitigate iron absorption using pH-sensitive multi-compartmental nanoparticulate oral delivery system.Nanomedicine. 2019 Nov;22:102091. doi: 10.1016/j.nano.2019.102091. Epub 2019 Oct 15. Nanomedicine. 2019. PMID: 31626992 Free PMC article.
-
Beta-thalassemia minor is associated with IgA nephropathy.Ann Lab Med. 2013 Mar;33(2):153-5. doi: 10.3343/alm.2013.33.2.153. Epub 2013 Feb 21. Ann Lab Med. 2013. PMID: 23479564 Free PMC article. No abstract available.
-
Acute renal failure following deferoxamine overdose.Pediatr Nephrol. 2003 Mar;18(3):283-5. doi: 10.1007/s00467-002-1051-7. Epub 2003 Feb 7. Pediatr Nephrol. 2003. PMID: 12644925
-
Renal function in children with beta-thalassemia major and thalassemia intermedia.Pediatr Nephrol. 2008 Oct;23(10):1847-51. doi: 10.1007/s00467-008-0897-8. Epub 2008 Jun 25. Pediatr Nephrol. 2008. PMID: 18581145
-
Renal dysfunction in patients with thalassaemia.Br J Haematol. 2011 Apr;153(1):111-7. doi: 10.1111/j.1365-2141.2010.08477.x. Epub 2011 Feb 21. Br J Haematol. 2011. PMID: 21332704 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical